11-4-03



CASE 100-8024D

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

FL987 587034US

Express Mail Label Number

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PATENT NO.: US 6,635,745 B2

ISSUED: October 21, 2003

INVENTOR(S): SEDRANI ET AL.

SERIAL NO: 09/757,212 FILED: JANUARY 9, 2001 FOR: RAPAMYCIN ASSAY

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION

Sir:

Patentees have discovered errors in (63) Related U.S. Application Data. Attached in duplicate is Form PTO-1050, with at least one copy being suitable for printing.

These errors are not ascribable to the Patentee. As such, there is no fee required for this Certificate of Correction.

These errors are material to the proper reading of the patent. Correction is therefore respectfully requested in accordance with 37 C.F.R. § 1.322.

Respectfully submitted,

Novartis Corporate Intellectual Property One Health Plaza, Building 430 East Hanover, NJ 07936-1080

Date: 1//3/03

Gabriel Lopez

Attorney for Applicants

Reg. No. 28,440

(862) 778-7882

Certificate

NOV 1 2 2003

of Correction

UNITED STATES PATENT AND TRADEMARK OFFICE **CERTIFICATE OF CORRECTION**

PATENT NO

US 6,635,745 B2

DATED:

October 21, 2003

INVENTOR(S)

SEDRANI ET AL.

It is certified that there is an error in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page, left column, section (63) should read:

(63) This is a continuation of Application 09/072,278, May 4, 1998, abandoned, which is a continuation of Application 08/532,837, October 5, 1995, abandoned, which is a 371 of PCT/EP94/01006, March 30, 1994. --

MAILING ADDRESS OF SENDER: Gabriel Lopez

Novartis

Corporate Intellectual Property One Health Plaza, Building 430

East Hanover, NJ 07936-1080

(862) 778-7882

FORM **PTO-1050**

PATENT NO. US 6,635,745 B2

UNITED STATES PATENT AND TRADEMARK OFFICE **CERTIFICATE OF CORRECTION**

PATENT NO.

: 6,635,745 B2

DATED

: October 21, 2003

INVENTOR(S) : Sedrani et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page,

Item [63], Related U.S. Application Data, should read:

-- [63] This is a continuation of Application 09/072,278, May 4, 1998, abandoned, which is a continuation of Application 08/532,837, October 5, 1995, abandoned, which is a 371 of PCT/EP94/01006, March 30, 1994. --

Signed and Sealed this

Page 1 of 1

Tenth Day of February, 2004

JON W. DUDAS Acting Director of the United States Patent and Trademark Office

Case: 100-8024D

UNITED STATES PATENT AND TRADEMARK OFFICE **CERTIFICATE OF CORRECTION**

PATENT NO

ÚS 6,635,745 B2

DATED:

October 21, 2003

INVENTOR(S)

SEDRANI ET AL.

It is certified that there is an error in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Item

Related U.S. Appl. Outry

Title page, left column, section (63), should read:

(63) This is a continuation of Application 09/072,278, May 4, 1998, abandoned, which is a continuation of Application 08/532,837, October 5, 1995, abandoned, which is a 371 of PCT/EP94/01006, March 30, 1994. --

MAILING ADDRESS OF SENDER:

Gabriel Lopez

Novartis

Corporate Intellectual Property One Health Plaza, Building 430

East Hanover, NJ 07936-1080

(862) 778-7882

FORM **PTO-1050**

PATENT NO. US 6,635,745 B2